|
|
|
| Effects of Dapagliflozin on serum chloride and short-term prognosis in patients with heart failure with reduced ejection fraction |
| LIU Yulian TANG Zengyao YANG Jiaquan LIU Jiwen |
| Department of Cardiovascular Medicine,Jiujiang First People's Hospital,Jiangxi Province,Jiujiang 332000,China |
|
|
|
|
Abstract Objective To observe the effect of Dapagliflozin on serum chloride and short-term prognosis in patients with heart failure with reduced ejection fraction (HFrEF).Methods A total of 106 patients with HFrEF admitted to the First People's Hospital of Jiujiang from August 2020 to March 2021 were selected as research objects,they were divided into the control group and the study group according to random number table method,with 53 cases in each group.The control group received routine clinical diagnosis and treatment of western medicine,while the study group received Dapagliflozin oral therapy on the basis of the control group for 3 months.Serum chloride ion concentration before and after treatment and prognosis after 6 months' treatment were compared between the two groups.Results The total effective rate of treatment of the study group was higher than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the serum chloride ion levels in the two groups were higher than those before treatment,and the serum chloride ion level of study group was higher than that of the control group,and the differences were statistically significant(P＜0.01).The rehospitalization rate in the study group was lower than that in the control group,and the difference was statistically significant (P＜0.01).Age,disease duration,baseline New York Heart Association (NYHA) classification,post-treatment chloride level and Dapagliflozin treatment were the influencing factors for the occurrence of end-point adverse events (P＜0.05).The logistic regression analysis showed that disease duration was a risk factor for end-point adverse events (OR=1.586,P＜0.05).Chloride ion level after treatment was a protective factor for preventing the occurrence of end-point adverse events (OR=0.924,P＜0.05).Conclusion Dapagliflozin can significantly improve the clinical treatment effect of patients with HFrEF.By improving the serum chloride ion level of patients,it can reduce the risk of adverse events in patients with end-point adverse events,which is worthy of clinical application.
|
|
|
|
|
|
|
|
|
